| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypothyroidism | 5 | 2025 | 77 | 3.080 |
Why?
|
| Thyroxine | 5 | 2025 | 59 | 3.050 |
Why?
|
| Environmental Exposure | 5 | 2025 | 290 | 1.800 |
Why?
|
| Graves Ophthalmopathy | 2 | 2024 | 17 | 1.510 |
Why?
|
| Addison Disease | 2 | 2022 | 4 | 1.460 |
Why?
|
| Astrocytes | 2 | 2026 | 278 | 1.420 |
Why?
|
| Hormone Replacement Therapy | 5 | 2025 | 214 | 1.360 |
Why?
|
| Triiodothyronine | 4 | 2025 | 54 | 1.330 |
Why?
|
| Neural Tube Defects | 3 | 2019 | 338 | 1.330 |
Why?
|
| Carcinoma, Neuroendocrine | 3 | 2021 | 41 | 1.250 |
Why?
|
| Thyroid Neoplasms | 5 | 2024 | 250 | 1.250 |
Why?
|
| Gene Regulatory Networks | 4 | 2023 | 384 | 1.190 |
Why?
|
| 46, XX Disorders of Sex Development | 2 | 2019 | 26 | 1.110 |
Why?
|
| Absorptiometry, Photon | 3 | 2026 | 198 | 1.060 |
Why?
|
| Retinal Ganglion Cells | 2 | 2026 | 115 | 1.060 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2024 | 93 | 0.970 |
Why?
|
| Optic Disk | 1 | 2026 | 46 | 0.920 |
Why?
|
| Pesticides | 2 | 2024 | 31 | 0.890 |
Why?
|
| Environmental Health | 1 | 2025 | 20 | 0.890 |
Why?
|
| Bone Density | 2 | 2025 | 369 | 0.890 |
Why?
|
| Glaucoma | 1 | 2026 | 88 | 0.880 |
Why?
|
| Adrenal Insufficiency | 2 | 2022 | 30 | 0.880 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2022 | 67 | 0.870 |
Why?
|
| Artifacts | 1 | 2025 | 104 | 0.850 |
Why?
|
| Lumbar Vertebrae | 1 | 2025 | 113 | 0.850 |
Why?
|
| Humans | 68 | 2026 | 130854 | 0.820 |
Why?
|
| Hot Flashes | 1 | 2023 | 6 | 0.800 |
Why?
|
| Homeodomain Proteins | 2 | 2026 | 568 | 0.790 |
Why?
|
| Smoking Cessation | 2 | 2025 | 191 | 0.770 |
Why?
|
| Retina | 8 | 2024 | 455 | 0.770 |
Why?
|
| Neurogenesis | 3 | 2023 | 220 | 0.760 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 568 | 0.750 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 1 | 2022 | 9 | 0.740 |
Why?
|
| Ependymoglial Cells | 3 | 2023 | 15 | 0.740 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2022 | 23 | 0.740 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2021 | 2849 | 0.730 |
Why?
|
| HLA Antigens | 2 | 2024 | 226 | 0.730 |
Why?
|
| Tissue Extracts | 1 | 2021 | 9 | 0.710 |
Why?
|
| Pituitary Diseases | 1 | 2021 | 9 | 0.710 |
Why?
|
| Female | 39 | 2025 | 70550 | 0.700 |
Why?
|
| Craniopharyngioma | 1 | 2021 | 34 | 0.700 |
Why?
|
| Galactosemias | 1 | 2021 | 14 | 0.700 |
Why?
|
| Health Status Disparities | 1 | 2025 | 277 | 0.700 |
Why?
|
| Congenital Abnormalities | 1 | 2025 | 323 | 0.700 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2021 | 3428 | 0.700 |
Why?
|
| Calciphylaxis | 1 | 2021 | 3 | 0.690 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2021 | 26 | 0.690 |
Why?
|
| Nerve Regeneration | 2 | 2024 | 74 | 0.680 |
Why?
|
| Brain Abscess | 1 | 2021 | 55 | 0.680 |
Why?
|
| Thyroid Gland | 1 | 2021 | 99 | 0.670 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2021 | 51 | 0.670 |
Why?
|
| Pituitary Neoplasms | 1 | 2021 | 81 | 0.670 |
Why?
|
| Male | 35 | 2025 | 64763 | 0.670 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 146 | 0.660 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2021 | 102 | 0.660 |
Why?
|
| Hypophosphatasia | 1 | 2020 | 2 | 0.660 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 214 | 0.650 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2025 | 226 | 0.650 |
Why?
|
| Leukemia | 1 | 2023 | 374 | 0.630 |
Why?
|
| Spinal Neoplasms | 1 | 2020 | 78 | 0.630 |
Why?
|
| Osteoporosis | 1 | 2021 | 133 | 0.620 |
Why?
|
| Calcinosis | 1 | 2021 | 181 | 0.610 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 507 | 0.610 |
Why?
|
| Skin Diseases | 1 | 2021 | 141 | 0.610 |
Why?
|
| Adult | 23 | 2026 | 31238 | 0.610 |
Why?
|
| Lymphoma | 1 | 2022 | 328 | 0.600 |
Why?
|
| Cellular Reprogramming | 1 | 2020 | 128 | 0.590 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 421 | 0.590 |
Why?
|
| Hypertension | 3 | 2023 | 1354 | 0.590 |
Why?
|
| Lactase | 1 | 2019 | 42 | 0.580 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 93 | 0.580 |
Why?
|
| DNA Methylation | 5 | 2024 | 1093 | 0.580 |
Why?
|
| Ventricular Remodeling | 1 | 2019 | 154 | 0.570 |
Why?
|
| Ventricular Function, Right | 1 | 2019 | 127 | 0.560 |
Why?
|
| Retinal Cone Photoreceptor Cells | 5 | 2024 | 74 | 0.560 |
Why?
|
| Celiac Disease | 1 | 2019 | 73 | 0.560 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 575 | 0.560 |
Why?
|
| Asthma | 3 | 2022 | 909 | 0.550 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2019 | 172 | 0.550 |
Why?
|
| Neuroblastoma | 1 | 2023 | 544 | 0.550 |
Why?
|
| Ovotesticular Disorders of Sex Development | 1 | 2017 | 2 | 0.550 |
Why?
|
| Gynecomastia | 1 | 2017 | 5 | 0.540 |
Why?
|
| Herniorrhaphy | 1 | 2018 | 72 | 0.540 |
Why?
|
| Heart Defects, Congenital | 3 | 2019 | 1876 | 0.530 |
Why?
|
| Tetralogy of Fallot | 1 | 2019 | 169 | 0.530 |
Why?
|
| Neoplasms | 4 | 2025 | 2955 | 0.530 |
Why?
|
| Cognitive Dysfunction | 2 | 2024 | 339 | 0.520 |
Why?
|
| Anti-Obesity Agents | 1 | 2017 | 47 | 0.520 |
Why?
|
| Epigenesis, Genetic | 5 | 2024 | 765 | 0.510 |
Why?
|
| Zebrafish | 3 | 2024 | 423 | 0.480 |
Why?
|
| Parkinson Disease | 1 | 2023 | 726 | 0.470 |
Why?
|
| Brain Neoplasms | 1 | 2025 | 1350 | 0.470 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 563 | 0.460 |
Why?
|
| Aged | 14 | 2025 | 20970 | 0.460 |
Why?
|
| Diabetes, Gestational | 1 | 2017 | 113 | 0.460 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 1414 | 0.460 |
Why?
|
| Diarrhea | 1 | 2017 | 313 | 0.450 |
Why?
|
| Risk Factors | 12 | 2026 | 10978 | 0.430 |
Why?
|
| Infant, Newborn | 7 | 2025 | 8509 | 0.420 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2026 | 331 | 0.410 |
Why?
|
| Middle Aged | 15 | 2025 | 28511 | 0.410 |
Why?
|
| Case-Control Studies | 7 | 2025 | 3393 | 0.410 |
Why?
|
| Societies, Medical | 3 | 2026 | 793 | 0.390 |
Why?
|
| Cross-Over Studies | 2 | 2025 | 324 | 0.370 |
Why?
|
| Endocrinology | 2 | 2026 | 128 | 0.370 |
Why?
|
| Retinal Degeneration | 3 | 2024 | 98 | 0.370 |
Why?
|
| CpG Islands | 2 | 2024 | 343 | 0.340 |
Why?
|
| Smoking | 3 | 2025 | 923 | 0.330 |
Why?
|
| Texas | 4 | 2025 | 3635 | 0.320 |
Why?
|
| Residence Characteristics | 2 | 2024 | 292 | 0.310 |
Why?
|
| Double-Blind Method | 2 | 2025 | 1639 | 0.310 |
Why?
|
| Infant | 6 | 2025 | 13299 | 0.300 |
Why?
|
| Calcitonin | 2 | 2021 | 29 | 0.300 |
Why?
|
| Child | 9 | 2025 | 26215 | 0.290 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2021 | 80 | 0.290 |
Why?
|
| Young Adult | 5 | 2025 | 10040 | 0.280 |
Why?
|
| Mothers | 2 | 2023 | 369 | 0.270 |
Why?
|
| Registries | 2 | 2025 | 1617 | 0.270 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2021 | 977 | 0.270 |
Why?
|
| United States | 7 | 2026 | 11865 | 0.260 |
Why?
|
| Joints | 1 | 2026 | 27 | 0.240 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 2303 | 0.240 |
Why?
|
| Aging | 2 | 2026 | 1257 | 0.240 |
Why?
|
| cis-trans-Isomerases | 2 | 2024 | 9 | 0.240 |
Why?
|
| Fractures, Stress | 1 | 2026 | 15 | 0.240 |
Why?
|
| Leber Congenital Amaurosis | 2 | 2024 | 34 | 0.230 |
Why?
|
| Triiodothyronine, Reverse | 1 | 2025 | 2 | 0.230 |
Why?
|
| Kyphoplasty | 1 | 2025 | 5 | 0.230 |
Why?
|
| Live Birth | 1 | 2025 | 64 | 0.230 |
Why?
|
| Smokers | 1 | 2025 | 48 | 0.220 |
Why?
|
| Genome-Wide Association Study | 3 | 2021 | 1842 | 0.220 |
Why?
|
| Drug Therapy, Combination | 2 | 2025 | 1170 | 0.220 |
Why?
|
| Athletic Injuries | 1 | 2026 | 76 | 0.220 |
Why?
|
| Particulate Matter | 1 | 2025 | 90 | 0.220 |
Why?
|
| Acromegaly | 1 | 2024 | 10 | 0.220 |
Why?
|
| Lung | 3 | 2022 | 1549 | 0.220 |
Why?
|
| Tobacco Products | 1 | 2025 | 60 | 0.220 |
Why?
|
| Immunoglobulins, Thyroid-Stimulating | 1 | 2024 | 2 | 0.220 |
Why?
|
| Receptors, Thyrotropin | 1 | 2024 | 8 | 0.220 |
Why?
|
| Air Pollution | 1 | 2025 | 76 | 0.220 |
Why?
|
| Thyroidectomy | 3 | 2024 | 101 | 0.220 |
Why?
|
| Oil and Gas Fields | 1 | 2024 | 10 | 0.210 |
Why?
|
| Exophthalmos | 1 | 2024 | 31 | 0.210 |
Why?
|
| Drug Repositioning | 1 | 2024 | 31 | 0.210 |
Why?
|
| Thyroid Nodule | 1 | 2024 | 22 | 0.210 |
Why?
|
| Rubella | 1 | 2024 | 18 | 0.210 |
Why?
|
| Adolescent | 5 | 2025 | 20818 | 0.210 |
Why?
|
| Phenotype | 3 | 2019 | 4482 | 0.210 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2024 | 12 | 0.210 |
Why?
|
| Multimorbidity | 1 | 2024 | 24 | 0.210 |
Why?
|
| Tobacco Smoking | 1 | 2024 | 21 | 0.210 |
Why?
|
| Measles | 1 | 2024 | 40 | 0.200 |
Why?
|
| Pain Management | 1 | 2026 | 206 | 0.200 |
Why?
|
| Neuroglia | 2 | 2023 | 224 | 0.200 |
Why?
|
| Chronic Pain | 1 | 2026 | 162 | 0.200 |
Why?
|
| Sweating | 1 | 2023 | 7 | 0.200 |
Why?
|
| Flushing | 1 | 2023 | 6 | 0.200 |
Why?
|
| Retinitis Pigmentosa | 1 | 2024 | 88 | 0.200 |
Why?
|
| Bone and Bones | 1 | 2026 | 307 | 0.200 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 4017 | 0.200 |
Why?
|
| Animals, Genetically Modified | 1 | 2024 | 327 | 0.200 |
Why?
|
| Zebrafish Proteins | 1 | 2024 | 133 | 0.200 |
Why?
|
| Animals | 12 | 2026 | 33981 | 0.190 |
Why?
|
| Sarcoma, Ewing | 1 | 2024 | 120 | 0.190 |
Why?
|
| Cosyntropin | 1 | 2022 | 4 | 0.190 |
Why?
|
| Wood | 1 | 2022 | 8 | 0.190 |
Why?
|
| Neurons | 2 | 2023 | 2023 | 0.190 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2022 | 60 | 0.190 |
Why?
|
| Headache | 1 | 2023 | 109 | 0.190 |
Why?
|
| Ceramidases | 1 | 2022 | 1 | 0.180 |
Why?
|
| Receptors, Adiponectin | 1 | 2022 | 5 | 0.180 |
Why?
|
| Child, Preschool | 4 | 2025 | 15016 | 0.180 |
Why?
|
| Orientia tsutsugamushi | 1 | 2021 | 1 | 0.180 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2021 | 5 | 0.180 |
Why?
|
| Scrub Typhus | 1 | 2021 | 7 | 0.180 |
Why?
|
| Quality of Life | 2 | 2022 | 2082 | 0.180 |
Why?
|
| Birth Weight | 1 | 2023 | 342 | 0.180 |
Why?
|
| Desiccation | 1 | 2021 | 47 | 0.180 |
Why?
|
| Hepatoblastoma | 1 | 2024 | 198 | 0.170 |
Why?
|
| Military Personnel | 1 | 2024 | 217 | 0.170 |
Why?
|
| Body Patterning | 1 | 2021 | 126 | 0.170 |
Why?
|
| Metanephrine | 1 | 2021 | 3 | 0.170 |
Why?
|
| Placebos | 1 | 2021 | 225 | 0.170 |
Why?
|
| Dexamethasone | 1 | 2022 | 251 | 0.170 |
Why?
|
| Pregnancy | 5 | 2025 | 7402 | 0.170 |
Why?
|
| Paraganglioma | 1 | 2021 | 22 | 0.170 |
Why?
|
| Hepatitis B | 1 | 2022 | 173 | 0.170 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 790 | 0.170 |
Why?
|
| Weight Gain | 1 | 2023 | 380 | 0.170 |
Why?
|
| Urinalysis | 1 | 2021 | 74 | 0.160 |
Why?
|
| Chickens | 1 | 2020 | 270 | 0.160 |
Why?
|
| Rats | 1 | 2026 | 3412 | 0.160 |
Why?
|
| Cell Lineage | 1 | 2021 | 345 | 0.150 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2021 | 216 | 0.150 |
Why?
|
| Retinal Diseases | 1 | 2022 | 151 | 0.150 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2019 | 4 | 0.150 |
Why?
|
| Mice | 9 | 2024 | 18267 | 0.150 |
Why?
|
| Androstenes | 1 | 2019 | 8 | 0.150 |
Why?
|
| Organogenesis | 1 | 2020 | 79 | 0.150 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2019 | 11 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 163 | 0.150 |
Why?
|
| Osteoblasts | 1 | 2020 | 177 | 0.150 |
Why?
|
| Genes, X-Linked | 1 | 2019 | 60 | 0.150 |
Why?
|
| Histone Deacetylases | 1 | 2020 | 130 | 0.150 |
Why?
|
| Gadolinium DTPA | 1 | 2019 | 49 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 3827 | 0.150 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2020 | 165 | 0.150 |
Why?
|
| Macular Degeneration | 1 | 2020 | 90 | 0.150 |
Why?
|
| Lymphoma, Follicular | 1 | 2019 | 32 | 0.150 |
Why?
|
| Gestational Age | 1 | 2023 | 1213 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2023 | 485 | 0.150 |
Why?
|
| Vietnam | 3 | 2025 | 65 | 0.150 |
Why?
|
| Fractures, Compression | 1 | 2019 | 12 | 0.150 |
Why?
|
| Biological Evolution | 1 | 2020 | 222 | 0.150 |
Why?
|
| Algorithms | 1 | 2026 | 1682 | 0.150 |
Why?
|
| Androgens | 1 | 2021 | 265 | 0.150 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 45 | 0.140 |
Why?
|
| Organoids | 1 | 2022 | 304 | 0.140 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2018 | 17 | 0.140 |
Why?
|
| Spinal Fractures | 1 | 2019 | 50 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 145 | 0.140 |
Why?
|
| Cognition | 1 | 2024 | 814 | 0.140 |
Why?
|
| Oxidoreductases | 1 | 2019 | 106 | 0.140 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 4682 | 0.140 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 292 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2021 | 415 | 0.140 |
Why?
|
| Skin | 1 | 2021 | 543 | 0.140 |
Why?
|
| Vision, Ocular | 1 | 2019 | 116 | 0.140 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 896 | 0.130 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 1167 | 0.130 |
Why?
|
| Octreotide | 1 | 2017 | 24 | 0.130 |
Why?
|
| Fibrosis | 1 | 2019 | 421 | 0.130 |
Why?
|
| Neck Dissection | 1 | 2017 | 29 | 0.130 |
Why?
|
| Poisson Distribution | 1 | 2017 | 50 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2024 | 17673 | 0.130 |
Why?
|
| Genetic Markers | 1 | 2019 | 597 | 0.130 |
Why?
|
| Metabolomics | 1 | 2021 | 506 | 0.130 |
Why?
|
| Gastrointestinal Agents | 1 | 2017 | 63 | 0.130 |
Why?
|
| Folic Acid | 1 | 2019 | 268 | 0.120 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 358 | 0.120 |
Why?
|
| DNA | 1 | 2022 | 1420 | 0.120 |
Why?
|
| Neck | 1 | 2017 | 142 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5199 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 824 | 0.120 |
Why?
|
| Contrast Media | 1 | 2019 | 491 | 0.120 |
Why?
|
| Prognosis | 1 | 2025 | 4910 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2019 | 1215 | 0.120 |
Why?
|
| Testis | 1 | 2017 | 397 | 0.110 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2016 | 79 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2026 | 1448 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2017 | 361 | 0.110 |
Why?
|
| Hypospadias | 1 | 2016 | 76 | 0.110 |
Why?
|
| Prevalence | 2 | 2024 | 2694 | 0.110 |
Why?
|
| Ovary | 1 | 2017 | 351 | 0.110 |
Why?
|
| Depression | 1 | 2024 | 1321 | 0.110 |
Why?
|
| Biomarkers | 1 | 2024 | 3400 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2021 | 12913 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1613 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 2112 | 0.110 |
Why?
|
| Health Behavior | 1 | 2017 | 389 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2021 | 1101 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2021 | 6448 | 0.100 |
Why?
|
| Weight Loss | 1 | 2017 | 527 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2024 | 2113 | 0.100 |
Why?
|
| HIV Infections | 1 | 2025 | 2036 | 0.100 |
Why?
|
| Genotype | 1 | 2019 | 2606 | 0.100 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2024 | 107 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 474 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1317 | 0.090 |
Why?
|
| Mutation | 2 | 2024 | 6138 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 2119 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2019 | 1605 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2017 | 1681 | 0.080 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2019 | 1157 | 0.080 |
Why?
|
| Eye Proteins | 2 | 2022 | 238 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 3807 | 0.080 |
Why?
|
| Retinal Rod Photoreceptor Cells | 2 | 2021 | 89 | 0.080 |
Why?
|
| Mice, Knockout | 3 | 2024 | 3836 | 0.080 |
Why?
|
| Retinal Pigment Epithelium | 2 | 2020 | 33 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2018 | 5095 | 0.070 |
Why?
|
| Chromatin | 2 | 2022 | 503 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 1395 | 0.060 |
Why?
|
| Autonomic Nerve Block | 1 | 2026 | 7 | 0.060 |
Why?
|
| Injections, Intra-Articular | 1 | 2026 | 34 | 0.060 |
Why?
|
| Female Athlete Triad Syndrome | 1 | 2026 | 3 | 0.060 |
Why?
|
| Peripheral Nerves | 1 | 2026 | 92 | 0.060 |
Why?
|
| Ferritins | 1 | 2026 | 107 | 0.060 |
Why?
|
| Minnesota | 1 | 2025 | 180 | 0.060 |
Why?
|
| Anesthetics, Local | 1 | 2026 | 86 | 0.060 |
Why?
|
| Prediabetic State | 1 | 2026 | 69 | 0.060 |
Why?
|
| Nerve Block | 1 | 2026 | 69 | 0.060 |
Why?
|
| Bromocriptine | 1 | 2024 | 7 | 0.050 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 6 | 1 | 2024 | 14 | 0.050 |
Why?
|
| Rubella Vaccine | 1 | 2024 | 3 | 0.050 |
Why?
|
| Rubella Syndrome, Congenital | 1 | 2024 | 3 | 0.050 |
Why?
|
| Rubella virus | 1 | 2024 | 5 | 0.050 |
Why?
|
| Hexachlorobenzene | 1 | 2024 | 2 | 0.050 |
Why?
|
| Measles Vaccine | 1 | 2024 | 12 | 0.050 |
Why?
|
| Indonesia | 1 | 2024 | 21 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2025 | 237 | 0.050 |
Why?
|
| Human Growth Hormone | 1 | 2024 | 75 | 0.050 |
Why?
|
| Air Pollutants | 1 | 2025 | 124 | 0.050 |
Why?
|
| Vitamin D | 1 | 2026 | 199 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 165 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 4715 | 0.050 |
Why?
|
| Immunization Programs | 1 | 2024 | 68 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2024 | 229 | 0.050 |
Why?
|
| Consensus | 1 | 2026 | 532 | 0.050 |
Why?
|
| India | 1 | 2024 | 244 | 0.050 |
Why?
|
| Maternal Exposure | 1 | 2024 | 150 | 0.050 |
Why?
|
| Dogs | 1 | 2024 | 616 | 0.050 |
Why?
|
| China | 1 | 2024 | 280 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2025 | 233 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2021 | 1935 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2024 | 171 | 0.050 |
Why?
|
| Iron | 1 | 2026 | 305 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2025 | 291 | 0.050 |
Why?
|
| Dried Blood Spot Testing | 1 | 2022 | 27 | 0.050 |
Why?
|
| Vital Capacity | 1 | 2022 | 90 | 0.050 |
Why?
|
| Immunoassay | 1 | 2022 | 125 | 0.050 |
Why?
|
| Regeneration | 1 | 2024 | 230 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2024 | 295 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2022 | 178 | 0.040 |
Why?
|
| Retinal Neurons | 1 | 2021 | 16 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2024 | 364 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2026 | 483 | 0.040 |
Why?
|
| Tooth, Deciduous | 1 | 2021 | 7 | 0.040 |
Why?
|
| NFI Transcription Factors | 1 | 2021 | 51 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2022 | 153 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2022 | 357 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2024 | 318 | 0.040 |
Why?
|
| Endotoxins | 1 | 2021 | 51 | 0.040 |
Why?
|
| Pheochromocytoma | 1 | 2021 | 32 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2020 | 52 | 0.040 |
Why?
|
| Photosensitivity Disorders | 1 | 2020 | 11 | 0.040 |
Why?
|
| Adenine | 1 | 2021 | 120 | 0.040 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2020 | 41 | 0.040 |
Why?
|
| Anthropometry | 1 | 2020 | 187 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2022 | 788 | 0.040 |
Why?
|
| Queensland | 1 | 2019 | 4 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1493 | 0.040 |
Why?
|
| Germany | 1 | 2019 | 59 | 0.040 |
Why?
|
| Species Specificity | 1 | 2020 | 482 | 0.040 |
Why?
|
| Calcium | 1 | 2024 | 1029 | 0.040 |
Why?
|
| Piperidines | 1 | 2021 | 230 | 0.040 |
Why?
|
| Stem Cells | 1 | 2024 | 715 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 276 | 0.040 |
Why?
|
| Retinaldehyde | 1 | 2019 | 9 | 0.040 |
Why?
|
| Transducin | 1 | 2019 | 32 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2019 | 29 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 418 | 0.040 |
Why?
|
| Chromosomes, Human, X | 1 | 2019 | 155 | 0.040 |
Why?
|
| North America | 1 | 2019 | 257 | 0.040 |
Why?
|
| Prednisone | 1 | 2019 | 239 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 689 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 1042 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 641 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2021 | 706 | 0.030 |
Why?
|
| Age Factors | 1 | 2024 | 2841 | 0.030 |
Why?
|
| Gene Expression | 1 | 2021 | 1492 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2019 | 654 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2021 | 968 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2023 | 2483 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2024 | 2454 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 1228 | 0.030 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 224 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 2212 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1712 | 0.020 |
Why?
|
| Transcriptome | 1 | 2019 | 1129 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 6217 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 6797 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 2612 | 0.020 |
Why?
|